We use cookies to understand how you use our site and to improve your experience. This includes personalizing content and advertising. To learn more, click here. By continuing to use our site, you accept our use of cookies, revised Privacy Policy and Terms of Service.
You are being directed to ZacksTrade, a division of LBMZ Securities and licensed broker-dealer. ZacksTrade and Zacks.com are separate companies. The web link between the two companies is not a solicitation or offer to invest in a particular security or type of security. ZacksTrade does not endorse or adopt any particular investment strategy, any analyst opinion/rating/report or any approach to evaluating individual securities.
If you wish to go to ZacksTrade, click OK. If you do not, click Cancel.
Celldex (CLDX) Presents Phase II Melanoma Study Data
Read MoreHide Full Article
Celldex Therapeutics, Inc. (CLDX - Free Report) presented results from a phase II study evaluating the combination of its pipeline candidates CDX-301 and CDX-1401 in patients with malignant melanoma at the annual meeting of the American Society of Clinical Oncology. The study was conducted by the Cancer Immunotherapy Trials Network under a Cooperative Research and Development Agreement between Celldex and the Cancer Therapy Evaluation Program of the National Cancer Institute.
Results from the study showed that the combination of CDX-1401 and CDX-301 generated significant NY-ESO-1 specific T cell responses in patients with melanoma. On the safety front, both combination regimens were found to be well tolerated with no drug-related adverse events being reported that required discontinuation of treatment.
Given the encouraging phase II study results, Celldex announced the initiation of a targeted study in patients with NY-ESO-1 positive disease to evaluate whether these enhanced immune responses can lead to improved clinical outcomes.
Currently, prescribed treatments for melanoma include drugs like Opdivo and Yervoy.
Apart from CDX-301 and CDX-1401, other candidates in Celldex’s pipeline include glembatumumab vedotin (phase II studies for triple negative breast cancer and metastatic melanoma), varlilumab (phase I/II, several combination studies across multiple types of cancer) and CDX-014 (phase I, renal cell carcinoma).
Celldex is a Zacks Rank #3 (Hold) stock. Some better-ranked stocks in the health care sector include ANI Pharmaceuticals, Inc. (ANIP - Free Report) and Retrophin, Inc. – both sporting a Zacks Rank #1 (Strong Buy) and Acorda Therapeutics, Inc. – carrying a Zacks Rank #2 (Buy).
Want the latest recommendations from Zacks Investment Research? Today, you can download 7 Best Stocks for the Next 30 Days. Click to get this free report >>
See More Zacks Research for These Tickers
Normally $25 each - click below to receive one report FREE:
Image: Bigstock
Celldex (CLDX) Presents Phase II Melanoma Study Data
Celldex Therapeutics, Inc. (CLDX - Free Report) presented results from a phase II study evaluating the combination of its pipeline candidates CDX-301 and CDX-1401 in patients with malignant melanoma at the annual meeting of the American Society of Clinical Oncology. The study was conducted by the Cancer Immunotherapy Trials Network under a Cooperative Research and Development Agreement between Celldex and the Cancer Therapy Evaluation Program of the National Cancer Institute.
Results from the study showed that the combination of CDX-1401 and CDX-301 generated significant NY-ESO-1 specific T cell responses in patients with melanoma. On the safety front, both combination regimens were found to be well tolerated with no drug-related adverse events being reported that required discontinuation of treatment.
Given the encouraging phase II study results, Celldex announced the initiation of a targeted study in patients with NY-ESO-1 positive disease to evaluate whether these enhanced immune responses can lead to improved clinical outcomes.
Currently, prescribed treatments for melanoma include drugs like Opdivo and Yervoy.
Apart from CDX-301 and CDX-1401, other candidates in Celldex’s pipeline include glembatumumab vedotin (phase II studies for triple negative breast cancer and metastatic melanoma), varlilumab (phase I/II, several combination studies across multiple types of cancer) and CDX-014 (phase I, renal cell carcinoma).
Celldex is a Zacks Rank #3 (Hold) stock. Some better-ranked stocks in the health care sector include ANI Pharmaceuticals, Inc. (ANIP - Free Report) and Retrophin, Inc. – both sporting a Zacks Rank #1 (Strong Buy) and Acorda Therapeutics, Inc. – carrying a Zacks Rank #2 (Buy).
Want the latest recommendations from Zacks Investment Research? Today, you can download 7 Best Stocks for the Next 30 Days. Click to get this free report >>